Tilmann Kramer

ORCID: 0000-0003-0265-7607
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pulmonary Hypertension Research and Treatments
  • Heart Failure Treatment and Management
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Cardiovascular Issues in Pregnancy
  • Cardiovascular Function and Risk Factors
  • High Altitude and Hypoxia
  • Cardiovascular Effects of Exercise
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Cardiovascular Disease and Adiposity
  • Cardiac Imaging and Diagnostics
  • Iron Metabolism and Disorders
  • Cardiac Arrhythmias and Treatments
  • EEG and Brain-Computer Interfaces
  • Respiratory Support and Mechanisms
  • Heart rate and cardiovascular health
  • Phonocardiography and Auscultation Techniques
  • Cardiovascular and Diving-Related Complications
  • ECG Monitoring and Analysis
  • Cardiovascular and exercise physiology
  • Protein Kinase Regulation and GTPase Signaling
  • Cardiac Ischemia and Reperfusion
  • Viral Infections and Immunology Research
  • Effects of Vibration on Health
  • Angiogenesis and VEGF in Cancer
  • Educational Robotics and Engineering

University Hospital Cologne
2017-2025

University of Cologne
2015-2025

Deutsches Zentrum für Luft- und Raumfahrt e. V. (DLR)
2022-2025

Centrum für Integrierte Onkologie
2022

Universities of Giessen and Marburg Lung Center
2015

Justus-Liebig-Universität Gießen
2015

University of Hawaii System
2015

Uppsala University
2015

The 2015 European pulmonary hypertension (PH) guidelines propose a risk stratification strategy for patients with arterial (PAH). Low-, intermediate- and high-risk strata are defined by estimated 1-year mortality risks of <5%, 5–10% >10%, respectively. This assessment awaits validation. We analysed data from newly diagnosed PAH enrolled into COMPERA (Comparative, Prospective Registry Newly Initiated Therapies Pulmonary Hypertension), European-based PH registry. An abbreviated version...

10.1183/13993003.00740-2017 article EN European Respiratory Journal 2017-08-01

Objective— Despite modern therapies, pulmonary arterial hypertension (PAH) harbors a high mortality. Vascular remodeling is hallmark of the disease. Recent clinical studies revealed that antiremodeling approaches with tyrosine–kinase inhibitors such as imatinib are effective, but its applicability limited by significant side effects. Although has multiple targets, expression analyses support role for platelet-derived growth factor (PDGF) in pathobiology However, precise and downstream...

10.1161/atvbaha.114.304864 article EN Arteriosclerosis Thrombosis and Vascular Biology 2015-03-06

<h3>Objective</h3> In patients with pulmonary arterial hypertension (PAH), supportive therapies may be beneficial in addition to targeted medical treatment. Here, we evaluated the effectiveness and safety of oscillatory whole-body vibration (WBV) on stable PAH therapy. <h3>Methods</h3> Twenty-two (mean PAP≥25 mm Hg wedge pressure (PAWP)≤15 Hg) who were world health organization (WHO)-Functional Class II or III therapy for≥3 months, randomised receive WBV (16 sessions 1-hour duration within 4...

10.1136/heartjnl-2016-309852 article EN cc-by-nc Heart 2017-01-18

Pulmonary arterial hypertension (PAH) is a progressive disease with limited survival. Iron deficiency (ID) correlates severity and mortality. While oral iron supplementation was shown to be insufficient in such patients, the potential impact of parenteral on clinical measures warrants further investigation.We retrospectively analysed long-term effects intravenous ferric carboxymaltose (FCM) status patients PAH ID [ferritin < 100 μg/L or ferritin 100-300 transferrin saturation (TSAT) 20%] who...

10.1002/jcsm.12764 article EN cc-by Journal of Cachexia Sarcopenia and Muscle 2021-09-09

Abstract Aims In pulmonary arterial hypertension (PAH), upfront combination therapy with ERA and PDE5i is associated a reduction in morbidity mortality events improves standard haemodynamics, but data remain limited. of this study were (i) to capture detailed haemodynamic effects rapid sequential dual patients newly diagnosed PAH; (ii) monitor the impact treatment initiation on clinical variables patients' risk status, (iii) compare effect ‘classical PAH’ ‘PAH co‐morbidities’. Methods Fifty...

10.1002/ehf2.14611 article EN cc-by-nc-nd ESC Heart Failure 2024-01-15

After longer duration space missions, some astronauts experience structural and functional changes in the eye brain, termed Spaceflight-Associated Neuro-Ocular Syndrome (SANS). Countermeasures against SANS are required to minimize potential operation impacts negative long-term health consequences. Headward fluid shifts, which appear promote SANS, provide a target for countermeasures. The countermeasures study, 30 days strict head down tilt bed rest (HDTBR) tested two mechanical aimed at...

10.3389/fphys.2025.1530783 article EN cc-by Frontiers in Physiology 2025-02-24

Abstract Electrocardiography (ECG) data are multidimensional temporal with ubiquitous applications in the clinic. Conventionally, these presented visually. It is presently unclear to what degree sonification (auditory display), can enable detection of clinically relevant cardiac pathologies ECG data. In this study, we introduce a method for polyphonic data, whereby different channels simultaneously represented by sound pitch. We retrospectively applied 12 samples from publicly available...

10.1038/srep44549 article EN cc-by Scientific Reports 2017-03-20

Neointima formation after vascular injury remains a significant problem in clinical cardiology, and current preventive strategies are suboptimal. Phosphatidylinositol 3'-kinase is central downstream mediator of growth factor signaling, but the role phosphatidylinositol isoforms remodeling elusive. We sought to systematically characterize precise catalytic class IA (p110α, p110β, p110δ), which signal receptor tyrosine kinases, for vivo.Western blot analyses revealed that all 3 abundantly...

10.1161/atvbaha.114.304887 article EN Arteriosclerosis Thrombosis and Vascular Biology 2015-04-24

Atrial septal defect (ASD) is one of the most frequent congenital heart diseases (CHD). Up to 10% adults with an ASD develop pulmonary arterial hypertension (PAH, PAH-CHD) in their lifetime. Despite improved therapy options, gravidity remains a substantial risk for both maternal and neonatal mortality PAH-CHD patients. In our patient, remained uncomplicated until week 32, under specific monotherapy tadalafil, before onset dyspnea markedly increase systolic pressure (PAP) was observed...

10.1177/2045894019835649 article EN cc-by-nc Pulmonary Circulation 2019-02-15

Myocardial fibrosis (MF) is associated with an increased predisposition to adverse cardiac events. The accumulation of high-volume and high-intensity exercise over extended duration potentially increases the risk MF. Specific electrocardiographic markers have been correlated presence This study assessed prevalence MF-related in a Track Field Master Athletics Cohort (TaFMAC).

10.1136/bmjsem-2024-001988 article EN cc-by-nc BMJ Open Sport & Exercise Medicine 2024-08-01

Abstract Background In pulmonary arterial hypertension (PAH), there is an excessive respiratory drive, which leads to inefficient ventilation with subsequent hypocapnia. Changes in blood gas analysis (BGA) may correlate symptom severity and outcome. Data on impact of targeted PAH therapy BGA are scarce it remains unclear if these values can be used for risk stratification purposes. Purpose To assess capillary at diagnosis evaluate the effect classical calculated parameters. Methods 147...

10.1093/eurheartj/ehac544.2186 article EN European Heart Journal 2022-10-01

Abstract Background Whether physically fit patients who have recovered from myocardial infarction can safely stay and exercise at high altitude is unclear. Myocardial tissue hypoxia pulmonary hypertension could affect cardiac function, electrophysiology predispose to arrythmias. Methods We included four non-professional male athletes (57.8 ± 3.3 years). All were clinically stable 37 104 months after left ventricular ST-elevation subsequent drug-eluting stenting of single-vessel coronary...

10.21203/rs.3.rs-2814437/v1 preprint EN cc-by Research Square (Research Square) 2023-05-18

Objective: In mice, normobaric hypoxia exposure corresponding to 8,000 m altitude after myocardial infarction reactivated cardiomyocyte proliferation and improved left ventricular ejection fraction (LVEF). Translating these findings patients might be limited by hypoxia-induced pulmonary hypertension ischemia. Design method: We conducted a feasibility safety study at the: envihab facility in 4 who had experienced with fully revascularized LAD-stenosis as culprit lesion 37-104 months prior...

10.1097/01.hjh.0000940744.18043.b2 article EN Journal of Hypertension 2023-06-01
Coming Soon ...